
Delivery of the first functional prototypes based on Intuity® Ject
EVEON, as part of a partnership with a pharmaceutical laboratory, has delivered, on schedule, the first functional prototypes based on the innovative medical device Intuity® Ject.
EVEON, as part of a partnership with a pharmaceutical laboratory, has delivered, on schedule, the first functional prototypes based on the innovative medical device Intuity® Ject.
EVEON is announcing that it has forged a partnership with a pharmaceutical laboratory for a development based on the innovative Intuity® Ject medical device, recipient of a 2017 Pharmapack Award.
EVEON and six French companies have sealed a unique partnership called JBT HubUp a unique solution for developing innovative medical devices.
A EVEON was awarded the special prize Ease of use and Patient compliance in the Best Innovation Exhibitor category at Pharmapack Europe 2017 for its Intuity® Ject device.
EVEON announces the release of its new prototype, which reconstitutes lyophilised drugs in just two steps, with no handling or contact with the product.
STMicroelectronics Grenoble and EVEON have signed a partnership agreement aimed at supplying components to be used in new generation medical devices developed by EVEON that will respond to the growing demand for injectable biological treatments.
EVEON was presented, in february 2016, with a Pharmapack Europe Award for its device Intuity® Lyo1 with the special distinction "Convenience and Easy of use".
EVEON reaches a major milestone in its development by signing a new industrial partnership agreement in oncology.
The company design an innovative medical device for cancer treatment in the framework of the "CARAT" project which is aimed at developing a French network of excellence in nuclear medicine.
EVEON signed an agreement with the pharmaceutical group Advanced Accelerator Applications for a medical injection device in oncology.
EVEON's objective is to develop and produce an innovative automated injection system for the treatment of solid tumours.